A licensing deal at the centre of the story

Argent BioPharma Ltd (ASX:RGT) is a clinical-stage biopharmaceutical company developing nano-engineered therapeutics for neurological and immune-mediated conditions. According to its FY2026 annual report, authorised for issue on 31 August 2026, its lead Assets are CannEpil, aimed at drug-resistant epilepsy, and CimetrA, aimed at inflammatory conditions. The angle that matters most is a binding transaction framework to license CannEpil globally to Splash Beverage Group, because the company links it directly to its funding position.

What the Annual Report shows

For the year ended 30 June 2026, Argent reported Revenue of A$161,187, compared with A$180,565 a year earlier. The net loss narrowed to A$7.71 million from A$17.84 million, helped by lower administrative expenses of A$6.86 million and Research and Development spending of A$0.49 million, down from A$3.59 million.

Under the Splash framework, Argent would receive a 15% Royalty on net revenues from CannEpil. The report describes the licensing conditions as still to be completed, so this is an agreed framework, not recognised revenue. The report also records a shipment of 1,000 CannEpil units to Ireland with an approximate reimbursed retail value of A$783,000. That is a retail value, not the amount Argent has booked.

Cash, Debt and going concern

Cash at 30 June 2026 was A$141,456, down from A$1.02 million a year earlier. Net operating cash outflow was A$4.03 million. The group had a Working Capital Deficit of A$8.08 million, net liabilities of A$9.45 million, and total assets of A$1.29 million.

The directors disclose a material uncertainty over going concern. They state that Argent must secure additional funding within 15 months and satisfy the conditions of the CannEpil licensing transaction. That is a formal accounting disclosure and should be read as a significant risk, not as a prediction of the outcome.

Two debt facilities feature. The first is a 2021 US$10 million convertible note Facility with Mercer, with about A$9.52 million of principal and interest outstanding and currently due. The report says that after year-end the parties agreed to extinguish the notes, with the Splash transaction forgiving about US$5.5 million. We could not read the full post-balance-date note, so the exact settlement terms are unconfirmed.

The second is an A$ convertible facility with C/M Capital and WVP of up to A$11 million. A$3 million was drawn in FY2026, and A$600,000 more was drawn after year-end, A$350,000 on 14 July and A$250,000 on 11 August 2026. The Maturity date was extended to 28 November 2026, which is the one confirmed date to watch. Share issue proceeds fell to A$271,978 from A$10.4 million, and the report lists 68.3 million Options and 20.1 million performance rights on issue, which are potential sources of dilution.

Other developments and sector context

On 13 April 2026 Argent acquired AusCann's 48% stake in CannPal Animal Therapeutics, adding a veterinary pipeline. It ceased Manufacturing at its Slovenian subsidiary, which was liquidated in December 2025, and Gary Hermon resigned as a director on 6 May 2026.

Cannabinoid-based and nano-formulated drugs face a long path through trials and regulators. Argent's specific risks include its dependence on a single licensing partner, a weak Balance Sheet and the time needed to show clinical or commercial traction. Clinical progress is not the same as regulatory approval, and the report does not describe an approval.